| HOME >> BIOLOGY >> TECHNOLOGY |
This year the ICAAC/IDSA meeting plans to host more than 12,000 attendees comprising physicians, clinicians and researchers working in the fields of clinical diagnostics, drug discovery and microbiology. For more information on Ibis involvement at the 48th Annual ICAAC/46th Annual IDSA Meeting, please visit the Ibis Web site at http://www.ibisbiosciences.com.
ABOUT IBIS T5000 BIOSENSOR SYSTEM AND IBIS BIOSCIENCES, INC.
Ibis Biosciences, Inc., a majority-owned subsidiary of Isis Pharmaceuticals, has developed and is commercializing the Ibis T5000(TM) Biosensor System for rapid identification and characterization of infectious agents. The Ibis T5000 is currently intended for research use only and not for use in diagnostic procedures. It is capable of identifying virtually all bacteria, viruses and fungi, and can provide information about drug resistance, virulence and strain type of these pathogens. Commercial applications for the Ibis T5000 Biosensor System include epidemiologic surveillance, monitoring of pandemic diseases, identification of emerging or previously unknown pathogens, forensic characterization of human samples, identification of sources of hospital-associated infections, and, in the future, human infectious disease diagnostics. Ibis develops, manufactures and markets Ibis T5000 instruments and assay kits. Ibis has entered into a distribution relationship under which Abbott will be selling Ibis products. Additional information about Ibis can be found by selecting the Ibis link from Isis' homepage at http://www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel
d
'/>"/>
| SOURCE Isis Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |